HK1051002A1 - Treatment of emphysema using rar selective retinoid agonists. - Google Patents

Treatment of emphysema using rar selective retinoid agonists.

Info

Publication number
HK1051002A1
HK1051002A1 HK03103206A HK03103206A HK1051002A1 HK 1051002 A1 HK1051002 A1 HK 1051002A1 HK 03103206 A HK03103206 A HK 03103206A HK 03103206 A HK03103206 A HK 03103206A HK 1051002 A1 HK1051002 A1 HK 1051002A1
Authority
HK
Hong Kong
Prior art keywords
emphysema
treatment
retinoid agonists
rar selective
selective retinoid
Prior art date
Application number
HK03103206A
Other languages
English (en)
Inventor
Paula Nanette Belloni
Michael Klaus
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1051002A1 publication Critical patent/HK1051002A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK03103206A 1999-10-19 2003-05-06 Treatment of emphysema using rar selective retinoid agonists. HK1051002A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19
PCT/EP2000/010076 WO2001030326A1 (en) 1999-10-19 2000-10-13 Treatment of emphysema using rar selective retinoid agonists

Publications (1)

Publication Number Publication Date
HK1051002A1 true HK1051002A1 (en) 2003-07-18

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103206A HK1051002A1 (en) 1999-10-19 2003-05-06 Treatment of emphysema using rar selective retinoid agonists.

Country Status (34)

Country Link
US (1) US6300350B1 (pl)
EP (1) EP1225878B1 (pl)
JP (2) JP4074458B2 (pl)
KR (1) KR100485581B1 (pl)
CN (1) CN1201730C (pl)
AR (1) AR029648A1 (pl)
AT (1) ATE344661T1 (pl)
AU (1) AU777325B2 (pl)
BR (1) BR0015225A (pl)
CA (1) CA2387844C (pl)
CY (1) CY1105941T1 (pl)
CZ (1) CZ20021657A3 (pl)
DE (1) DE60031790T2 (pl)
DK (1) DK1225878T3 (pl)
ES (1) ES2274810T3 (pl)
HK (1) HK1051002A1 (pl)
HR (1) HRP20020329A2 (pl)
HU (1) HUP0203295A3 (pl)
IL (1) IL149151A0 (pl)
JO (1) JO2178B1 (pl)
MA (1) MA26835A1 (pl)
MX (1) MXPA02003843A (pl)
MY (1) MY129001A (pl)
NO (1) NO328738B1 (pl)
NZ (1) NZ518118A (pl)
PE (1) PE20010678A1 (pl)
PL (1) PL357499A1 (pl)
PT (1) PT1225878E (pl)
RS (1) RS50165B (pl)
RU (1) RU2257383C2 (pl)
TR (1) TR200201071T2 (pl)
TW (1) TWI288639B (pl)
WO (1) WO2001030326A1 (pl)
ZA (1) ZA200202576B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
CN1283621C (zh) 2001-09-18 2006-11-08 霍夫曼-拉罗奇有限公司 烷基脲的类维生素a激动剂ⅰ
CN1301968C (zh) 2001-09-18 2007-02-28 霍夫曼-拉罗奇有限公司 取代的脲的类维生素a激动剂ⅱ
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
ES2481167T3 (es) 2003-08-22 2014-07-29 Dupont Nutrition Biosciences Aps Composición que comprende una bacteriocina y un extracto de una planta de la familia Labiatae
US20100222304A1 (en) * 2006-11-02 2010-09-02 Lillian W Chiang Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis
DK2613776T3 (da) 2010-09-01 2020-10-19 Univ Jefferson Sammensætning og fremgangsmåde til muskelreparation og -regenerering
RU2678561C9 (ru) 2011-06-24 2019-03-05 ДжиАрАй Био, Инк. Предупреждение и лечение воспалительных состояний
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013019653A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
AU2013363215B2 (en) 2012-12-17 2018-03-01 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
EP3150585A1 (en) 2012-12-17 2017-04-05 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
WO2015026990A2 (en) 2013-08-20 2015-02-26 University Of Washington Through Its Center For Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydrolase
WO2015041809A2 (en) 2013-08-26 2015-03-26 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0139216B1 (ko) 1988-04-11 1998-05-01 제임스 엠. 캐내지 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) * 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
KR20010032000A (ko) * 1997-11-12 2001-04-16 프리돌린 클라우스너, 롤란드 비. 보레르 레티노이드 길항제를 이용한 티-보조 세포 제2형 중재면역 질환의 치료
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
AU4222400A (en) 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
AU4225500A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
AU772551B2 (en) * 1999-08-02 2004-04-29 F. Hoffmann-La Roche Ag New selective retinoid agonists
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
TWI288639B (en) 2007-10-21
CA2387844C (en) 2009-04-14
CN1382042A (zh) 2002-11-27
PT1225878E (pt) 2007-01-31
PL357499A1 (pl) 2004-07-26
JP4850791B2 (ja) 2012-01-11
NZ518118A (en) 2004-02-27
AU777325B2 (en) 2004-10-14
AR029648A1 (es) 2003-07-10
PE20010678A1 (es) 2001-07-04
CY1105941T1 (el) 2011-04-06
NO328738B1 (no) 2010-05-03
MY129001A (en) 2007-03-30
NO20021823L (no) 2002-04-18
MA26835A1 (fr) 2004-12-20
KR100485581B1 (ko) 2005-04-27
DK1225878T3 (da) 2007-03-05
YU29002A (sh) 2005-06-10
TR200201071T2 (tr) 2002-08-21
JO2178B1 (en) 2003-04-23
IL149151A0 (en) 2002-11-10
RU2257383C2 (ru) 2005-07-27
JP2003512418A (ja) 2003-04-02
AU1137401A (en) 2001-05-08
JP4074458B2 (ja) 2008-04-09
EP1225878A1 (en) 2002-07-31
JP2007302689A (ja) 2007-11-22
CN1201730C (zh) 2005-05-18
HUP0203295A3 (en) 2003-04-28
DE60031790D1 (de) 2006-12-21
RS50165B (sr) 2009-05-06
NO20021823D0 (no) 2002-04-18
CZ20021657A3 (cs) 2002-10-16
ES2274810T3 (es) 2007-06-01
BR0015225A (pt) 2002-07-16
KR20020043640A (ko) 2002-06-10
MXPA02003843A (es) 2002-09-30
CA2387844A1 (en) 2001-05-03
US6300350B1 (en) 2001-10-09
DE60031790T2 (de) 2007-09-20
WO2001030326A1 (en) 2001-05-03
ZA200202576B (en) 2003-09-23
HRP20020329A2 (en) 2004-04-30
HUP0203295A2 (hu) 2003-01-28
EP1225878B1 (en) 2006-11-08
ATE344661T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
IL149874A0 (en) Selective photothermolysis
HK1051002A1 (en) Treatment of emphysema using rar selective retinoid agonists.
AU3660699A (en) Uterine treatment apparatus
MXPA02003669A (es) Modificacion del tiempo de floracion.
AU2001295032A1 (en) Iontophoretic apparatus
ZA200108446B (en) Novel method of treatment.
MXPA02002646A (es) Aparato para tratamiento de agua.
EP1210915A3 (en) Laser treatment apparatus
AU2001252605A1 (en) Laser treatment apparatus
ZA200107824B (en) Apparatus.
MXPA03002861A (es) Nuevos retinoides para tratamiento del enfisema.
ZA200207489B (en) Apomorphine derivatives and methods for their use.
AU2002212885A1 (en) Alarm apparatus
HK1030590A1 (en) Crane apparatus.
AUPQ989400A0 (en) Water treatment apparatus
MXPA03004017A (es) Metodo para el tratamiento de inflamacion.
MXPA03005569A (es) PROCEDIMIENTO MEJORADO PARA LA PREPARACION DE UN FARMACO ANTIMIGRAnOSO.
SG89379A1 (en) Treatment apparatus
HK1045053A1 (en) Treatment solution and treatment method for reducing copper oxides.
HK1048939A1 (en) Chemical peeling agent.
ZA200109120B (en) Use of Arylalkanoylpyridazines.
AU2504101A (en) Device for carrying out the oscillation-induced selective treatment of malignantdiseases
ZA200007396B (en) Method of treatment.
SI1225878T1 (sl) Rar-gama selektivni retinoidni agonisti za zdravljenje emfizema
AU2002223293A1 (en) Water treatment apparatus

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111013